Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,09
KB-0,66
PKN99,7101-0,35
Msft0,95
Nokia4,834,8332,11
IBM0,42
Daimler AG55,7755,790,65
PFE1,16
19.9.2018 5:01:38
Indexy online
AD Index online
select
AD Index online
 

  • 18.9.2018 22:00:00
Aldexa Therap (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
7,85 2,61 0,20 73 619
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.9.2018
Popis společnosti
Obecné informace
Název společnostiAldeyra Therapeutics Inc
TickerALDX
Kmenové akcie:Ordinary Shares
RICALDX.O
ISINUS01438T1060
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky30.6.2018
Počet zaměstnanců k 31.12.2014 6
Akcie v oběhu k 9.8.2018 20 974 920
MěnaUSD
Kontaktní informace
Ulice131 Hartwell Ave Ste 320
MěstoLEXINGTON
PSČ02421-3105
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon17 817 614 904
Fax13026365454

Business Summary: Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
Financial Summary: BRIEF: For the six months ended 30 June 2018, Aldeyra Therapeutics Inc revenues was not reported. Net loss increased 68% to $17.4M. Higher net loss reflects Interest Exp-Net of Capitalized Interest increase of 2% to $54K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.72 to -$0.89.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSPharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 19.9.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorTodd Brady4623.1.201223.1.2012
Chief Financial OfficerJoshua Reed4527.7.201827.7.2018
Chief Operating OfficerScott Young51
Senior Vice President - Corporate Development and StrategyDavid McMullin-10.5.201810.5.2018
Chief Medical OfficerDavid Clark-11.1.201611.1.2016